Previous 10 | Next 10 |
home / stock / dsnky / dsnky news
Daiichi Sankyo Company Limited (DSKYF) Q2 2022 Earnings Conference Call October 29, 2021 2:30 AM ET Company Participants Sunao Manabe - President, Group CEO & Representative Director Wataru Takasaki - Executive Officer and Head of R&D Division Conference Call Participants Kazuaki Hash...
The FDA has granted AstraZeneca's (NASDAQ:AZN) Enhertu (trastuzumab deruxtecan), Breakthrough Therapy Designation (BTD) in U.S. for the treatment of adult patients with HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. Breakthrough Therapy status provid...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with this event. For further details see: Daiichi Sankyo Company Limited (DSKYF) ESMO 2021Virtual Congress Presentation - Slideshow
AstraZeneca (NASDAQ: AZN) is making headlines again, and this time it has nothing to do with the big pharmaceutical company's COVID-19 vaccine. The European Society for Medical Oncology held its annual conference over the weekend and Enhertu, a new breast cancer drug from AstraZenec...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Allegations of fraud against Cassava Sciences (NASDAQ: SAVA ) are unlikely to stop its Alzheimer’s drug candidate from quickly advancing to a Phase 3 clinical trial. As a result, I remain very bullish on SAVA s...
Daiichi Sankyo Company Limited (DSKYF) Q1 2022 Results Conference Call July 30, 2021 2:00 AM ET Company Participants Hiroyuki Okuzawa - Head of Corporate Planning & Management Division, CFO Wataru Takasaki - Head of R&D Division Conference Call Participants Kazuaki Hashiguchi - Daiwa ...
Roland Magnusson/iStock Editorial via Getty Images Today, AstraZeneca (AZN) and Daiichi Sankyo Company (DSKYF), (DSNKY) announced that the first patient was dosed in a Phase 3 trial designed to evaluate ENHERTU (trastuzumab deruxtecan) in a subset of patients with gastric or gastroesophageal ...
loops7/E+ via Getty Images Daiichi Sankyo (DSNKY) is ending development of nafamostat as a potential therapy for COVID-19, Reuters reports. The Japanese drugmaker did not give a reason for abandoning the program. However, Japan's Nikkei newspaper said there were safety concerns. Nafamostat is...
AstraZeneca's innovative culture earned it a place as one of the leading biotechs globally. Revenue growth from COVID vaccine sales and some key markets provide strong tailwinds for the company's share in the second half of 2021. Most of AstraZeneca's revenue comes from a handful ...
Daiichi Sankyo Company Limited (DSKYF) Q4 2020 Earnings Conference Call April 27, 2021 3:00 AM ET Company Participants Sunao Manabe - President and CEO Wataru Takasaki - Head, R&D Division Hiroyuki Okuzawa - Head of Corporate Planning & Management Division and CFO Conference Call Part...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Sponsored ADR Level 1 Company Name:
DSNKY Stock Symbol:
OTCMKTS Market:
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
2023-10-31 10:15:00 ET Big pharmas have the resources to make big, multi-year moves that can reshape or even redefine their businesses. As you may know, Merck (NYSE: MRK) is one of the largest of the big pharmas, with a market capitalization of $262 billion, and it just made one of ...
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire TOKYO and OSAKA, Japan , Dec. 21, 2022 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO:...